Search PubMedSearch

Biomedical subjects

K R Carlson

Publications and source records attributed to K R Carlson.

At least 19 recordsLinked to original sources

Etonitazene: an opioid selective for the mu receptor types.

Specific radioligand binding protocols were utilized to compare the affinity of morphine and the high-potency opioid etonitazene at mu 1, mu 2, delta, kappa 1 and sigma receptors. Both etonitazene and morphine displayed a mu 1-selective binding profile; however, etonitazene had a 2500-fold higher affinity at this receptor type. The latter result is consistent with the relative potencies or morphine and etonitazene in various behavioral tests.

Amino Acid Sequence

Augmentation of morphine-induced changes in brain monoamine metabolism after chronic naltrexone treatment.

To investigate the role of opioid mechanisms in the regulation of cerebral monoaminergic neurons, male Wistar rats were continuously infused with naltrexone via an Alzet osmotic minipump, or were sham-implanted, for 14 days. Twenty-four hours after removal of the pumps or sham implants, the rats were given s.c. morphine (3, 10 or 30 mg/kg) or saline and were sacrificed 2 hr postinjection. Eight brain regions were assayed for dopamine, 5-hydroxytryptamine, noradrenaline and their respective metabolites. Chronic naltrexone treatment per se caused only small changes in cerebral monoamines. Morphine elevated dose-dependently the cerebral concentrations of the acidic dopamine metabolites, 3,4-dihydroxyphenylacetic acid and homovanillic acid, as well as that of the 5-hydroxytryptamine metabolite, 5-hydroxyindoleacetic acid, and that of the noradrenaline metabolite, free 3-methoxy-4-hydroxyphenylethyleneglycol. In naltrexone-pretreated rats these elevations were significantly larger. Furthermore, in the naltrexone-pretreated rats 10 mg/kg of morphine significantly decreased the concentration of the dopamine metabolite 3-methoxytyramine both in the striatum and in the limbic forebrain, whereas in the control rats the 3-methoxytyramine content fell first after the 30-mg/kg dose and only in the striatum. Thus, both the stimulatory and the inhibitory effects of morphine on cerebral monoaminergic neurons seem to be potentiated by chronic naltrexone treatment. These data suggest that the activity of cerebral monoaminergic systems is to some degree regulated by an endogenous opioid input. When that input is chronically blocked, the basal metabolism of monoamines is not much altered but the systems' responsiveness to agonist challenge is increased.

Animals

Taste vs. CNS effects in voluntary oral opiate intake: studies with a novel device and technique.

An apparatus is described which negates the influence of rats' position preferences by presenting alternative solutions at the same location. The licks for both solutions were monitored over consecutive short intervals by lick detectors with computer capture of data. Rats given a choice between water and dilute solutions of the high-potency opiates etonitazene (1.0-5.0 micrograms/ml) or fentanyl (10-50 microgram/ml) either licked equally for the two solutions, or gradually developed a preference or aversion regarding the opiate over the course of several days. In contrast, preferential licking for solutions with a definite taste, saccharin or quinine, was established in hours. These data indicate that the taste per se of these opiates is not aversive to rats, and that preferences for or aversions to the opiates have some other base, presumably one or more actions on the central nervous system.

Animals

Changes in brain monoamine metabolism during withdrawal from chronic oral self-administration of morphine and in response to a morphine challenge in the withdrawn state.

Although p.o. self-administration of morphine is a reliable and convenient means of inducing physical dependence, its effects on brain monoamine metabolism have not been determined. Accordingly, in the present experiment young Wistar rats drank increasing concentrations (0.1-0.5 mg/ml) of morphine in water, or water alone, for 37 days. Half the rats in each group were challenged with morphine (10 mg/kg s.c.) when 27 to 29 hr withdrawn, and half with saline. Rats were sacrificed 2 hr postinjection. Seven brain regions were analyzed for noradrenaline (NA), dopamine (DA), or 5-hydroxytryptamine (5-HT), and their respective metabolites. In all cases in which a comparison could be made with prior work utilizing repeated injections to produce dependence, the p.o. regimen produced the same effects. Thus, the mode of administration does not seem to modify the response of monoaminergic neurons to chronic morphine. In withdrawal, NA turnover increased but DA and 5-HT turnovers decreased. Acute morphine accelerated the turnover of all three monoamines. The NA response was attenuated in some brain regions of withdrawn rats, indicating the development of tolerance to the turnover-enhancing effect of acute morphine in noradrenergic neurons. In contrast, the effect of acute morphine on cerebral 5-HT turnover was not altered, and its effect on cerebral DA turnover was enhanced in withdrawn rats. Our results suggest that there are fundamental differences among the three monoaminergic systems in their capacities for adapting to chronic morphine treatment.

3,4-Dihydroxyphenylacetic Acid

Comparison of regional CNS ligand binding in two inbred rat strains: effects of chronic morphine.

Male rats of the F-344 and BUF inbred strains were given free access to a 10% sucrose solution containing 0.5 mg/ml morphine sulfate (controls received sucrose only) as their sole source of fluids. The daily intake of morphine averaged 101 +/- 13 mg/kg. After 18 days on this regimen, animals were sacrificed and assayed for 3H-clonidine (alpha-2 adrenergic), 3H-dihydroalprenolol (DHA, beta 1 and 2 adrenergic) and 3H-spiperone (SPD, 5-HT2 and D2) binding in several brain regions. In the absence of morphine treatment, BUF rats displayed higher levels of SPD binding in brainstem, as compared with the F-344 strain. In contrast, untreated F-344 rats exhibited higher levels of DHA binding in hypothalamus and SPD binding in striatum than BUF rats. Chronic morphine resulted in an increase in clonidine and DHA binding in the brainstem and hippocampus respectively of BUF, but not F-344 rats, suggesting a greater sensitivity of adrenergic function to opiate treatment in the BUF strain. The two strains differed qualitatively in the effect of morphine on striatal SPD binding, with BUF rats exhibiting a decrease, and F-344 rats an increase. The one consistent change observed in both strains was a quantitatively similar increase in hippocampal SPD binding after chronic morphine. The results demonstrate that despite strain-dependent differences in binding characteristics, chronic morphine elicits a strain-independent alteration in hippocampal 5-HT2 binding. On the basis of these preliminary findings, it may be speculated that this particular neurochemical consequence contributes to morphine-induced behaviors which are observed independent of rat strain.

Animals

Morphine dependence and protracted abstinence: regional alterations in CNS radioligand binding.

Rats (Fisher F-344) were given free access to a 10% sucrose solution containing 0.5 mg/ml morphine sulfate (controls received the sucrose vehicle only) as their sole source of fluid. Daily morphine intake averaged 119 +/- 21 mg/kg, an amount sufficient to induce physical dependence. After 18 days on this regimen, the control and dependent subjects were sacrificed. A protracted abstinence group was weaned from morphine by reducing its concentration in the vehicle by 20% over the next 5 days, followed by a 5-week drug-free period before sacrifice concurrent with the other groups. These subjects showed no signs of an abstinence syndrome. Binding assays for alpha-2 adrenergic sites (3H-clonidine), beta-1/beta-2 adrenergic sites (3H-dihydroalprenolol), and dopaminergic (D2)/serotonergic (5-HT2) sites (3H-spiroperidol) were performed on tissue from frontal cortex, hippocampus, striatum, and brainstem. No alterations in 3H-clonidine or 3H-dihydroalprenolol binding were observed in dependence or protracted abstinence, suggesting that noradrenergic systems are well-regulated both during dependence and in protracted abstinence. 3H-spiroperidol binding was significantly elevated in the striatum (D2 sites) and hippocampus (5-HT2 sites) during dependence. Hippocampal 3H-spiroperidol binding returned to control levels in protracted abstinence, reflecting a morphine-induced change in 5-HT2 binding sites which had normalized by 5 weeks post-drug. Striatal 3H-spiroperidol binding was significantly decreased below control levels after withdrawal, suggesting that alterations of D2 sites in this structure may play a role in protracted abstinence.

Animals

Rapid determination of dopamine uptake in synaptosomal preparations.

A rapid method for assay of dopamine uptake in synaptosomal preparations involving reisolation of radiolabeled synaptosomes by rapid centrifugation is described. Utilizing this technique it was found that dopaminergic synaptosomes are relatively short lived, thus emphasizing the importance of rapid assay following tissue preparation. The effects of d-amphetamine, nomifensine and amfonelic acid were tested using the new procedure. The results of these experiments show a relative potency of uptake inhibition by these compounds which is comparable to previously published data.

Animals

Interaction of opiates with dopamine receptors: receptor binding and behavioral assays.

We examined the hypothesis that opiates act as dopamine (DA) receptor-blocking agents thereby inducing a compensatory increase in DA receptor density during chronic administration, and that increased receptor density could account for the behavioral hypersensitivity to DA agonists seen after treatment with opiates. Morphine and methadone did not inhibit the specific binding of 3H-spiroperidol to DA receptors in vitro, nor did they decrease affinity or apparent receptor density in the striatum when administered acutely in vivo in behaviorally effective doses. In contrast, neuroleptics had the expected inhibitory effect in both these experiments. Stereotypy and locomotion in response to apomorphine were measured before and after a 3-week treatment with saline or methadone. About half the methadone-treated rats showed significant increases over predrug baselines in stereotypy or locomotion, as did a few saline-treated animals. However, in those animals showing enhanced stereotypy or locomotion, DA receptor density was not elevated in striatum or mesolimbic areas respectively. These results indicate that opiates do not act as antagonists at DA receptor sites, and that changes in DA receptor density cannot account for opiate-induced behavioral hypersensitivity.

Animals

Pentobarbital induces a naloxone-reversible decrease in mesolimbic self-stimulation threshold.

The effects of sodium pentobarbital and naloxone were tested on intracranial self-stimulation (ICSS) in rats implanted with electrodes in the ventral tegmental area. Threshold for ICSS was determined using a rate-independent current titration paradigm. A low dose of pentobarbital (5 mg/kg) did not have a significant effect on ICSS thresholds, while a high dose (20 mg/kg) rendered the subjects too ataxic to respond reliably in the operant task. An intermediate dose (10 mg/kg) induced a highly significant lowering of threshold (17% below saline baseline levels) without apparent deterioration in response capability. The concurrent administration of naloxone (2 mg/kg) significantly reversed the pentobarbital-induced threshold decrease, while naloxone treatment alone had no effect on the ICSS threshold.

Animals

Time course of dopaminergic hypersensitivity following chronic narcotic treatment.

Guinea pigs were injected SC for 3 weeks with 3 different dosage schedules of morphine or methadone, or with saline. For 8 weeks thereafter they were challenged weekly with the dopamine agonist apomorphine. Hypersensitivity was manifested in more intense stereotypies, as compared to the saline group, by all morphine and methadone groups. Hypersensitivity persisted longer after the termination of methadone treatment (maximum of 8 weeks) than after morphine administration (maximum of 3 weeks). The degree of hypersensitivity, and its duration after treatment, was positively related to methadone dosage. In some groups a period of hyposensitivity was seen following hypersensitivity. These data are interpreted with reference to the hypothesized mechanism underlying the development of hypersensitivity, the different durations of action of morphine and methadone, and the retention of methadone in brain following treatment.

Animals

Behavioral supersensitivity to apomorphine following chronic narcotic treatment in the guinea pig.

Male albino guinea pigs were treated for 3 weeks with methadone, morphine, haloperidol, or saline. One week and 5 weeks following termination of treatment they were challenged with the directly acting dopaminergic agonist apomorphine. At the week 1 test the haloperidol and saline groups did not differ, but behavioral supersensitivity was apparent in significantly elevated mean stereotypy scores of the methadone and morphine groups relative to the saline group. The source of differences in mean scores was a higher peak score rather than increased duration of action. At the week 5 test the scores of the methadone group were even higher, the morphine group's scores were equivalent to the saline group's, and the haloperidol group's scores were significant depressed. This study indicates that a 3-week treatment period with methadone or morphine is sufficient to induce dopaminergic supersensitivity and suggests that there may be different time courses for the retention or expression of supersensitivity following these narcotics.

Animals

Sensitivity to apomorphine in the guinea pig as a function of age and body weight.

Male albino guinea pigs aged 4--10 weeks were challenged with 0.1, 0.2, and 0.4 mg/kg apomorphine. Mean stereotypy scores rose signfiicantly as a function of age. Stereotypy scores were better correlated with age than with body weight, suggesting that CNS maturation, rather than weight-related factors, were responsible. Although age and body weight were correlated, there was enough variability to make bvody weight an unreliable indicator of age.

Aging

Effect of chronic oral methadone treatment on the growth of maturing monkeys.

Three male rhesus monkeys drank methadone hydrochloride (1.0-2.5 mg/kg/day) in Tang orange drink from age two to four years. Their rate of body weight gain was faster than that found by other experimenters. In a second study one male monkey drank 2.0 mg/kg/day methadone while two others drank only Tang from age 21/2 to 31/2 years. The rate of body weight gain was identical for the three monkeys, and was the same as that found in the previous study. The apparent augmentation of body weight gain in the first study was probably due to inter-laboratory differences in housing and feeding conditions.

Age Factors

Behavioral evidence for dopaminergic supersensitivity following chronic treatment with methadone or chlorpromazine in the guinea pig.

This study demonstrated the enhancement, as a consequence of prior chronic drug treatment, of two behaviors (stereotyped oral behaviors and open field locomoation) which are thought to depend primarily on the striatel dopamine system. Following a 5-week treatment with methadone (MD), chlorpromazine (CPZ), or saline, the dopamine agonist methamphetamine (MA) elicited more intense stereotypies in the MD and CPZ animals. After chronic treatment with MD, the MA-elicited stereotypies were reduced by an acute dose of MD. Stereotyped oral behaviors elicited by a stressful stimulus (foot shock) were enhanced in the MD animals both during and following chronic drug treatment. MA-elicited open field locomotion, measured 2 weeks following termination of chronic drug treatment, was enhanced in the MD and CPZ animals.

Animals

Dyskinesias in monkeys: interaction of methamphetamine with prior methadone treatment.

Rhesus monkeys with a history of drinking methadone, but presently drug-free, were injected with low doses of methamphetamine (MA). They immediately developed oral dyskinesias resembling the symptoms of tardive dyskinesia in humans, a condition resulting from chronic blockade of striatal dopamine receptors by neuroleptics. Nine of 11 control monkeys failed to develop dyskinesias during prolonged MA administration. A stressful stimulus intensified the MA-elicited oral dyskinesias, an effect analogous to exacerbation of tardive dyskinesias by emotional stress. Control monkeys were then injected with methadone, chlorpromazine, haloperidol, or saline for 45 days. Ten days following this chronic treatment, MA immediately elicted oral dyskinesias in the methadone and chlorpromazine monkeys. Acute administration of the dopaminergic blocking agents chlorpromazine, spiroperidol, and clozapine eliminated MA-elicited dyskinesias, whereas the alpha-adrenergic blocker phentolamine was ineffective. Physostigmine blocked the dyskinesias in 1 of 2 cases. Sedative doses of phenobarbital and diazepam had no effect on oral dyskinesias. These data indicate that chronic treatment with methadone or other dopamine receptor blocking agents leads to receptor supersensitivity to the actions of MA.

Animals